Check out our webinar covering how pharmaceutical manufacturers can utilize channel data analytics to drive monitoring and auditing of their 340B programs.  

IntegriChain Director of Solution Engineering Dave Weiss and guest speaker Michael Townsend, IDC Health Insights Research Manager, Life Sciences Business Systems Strategies explore the changing breadth of the 340B Discount Drug Program and the insights offered in the Health Resources and Services Administration’s (HRSA’s) recently released mega-guidance, including results of its program-integrity audits.